Welcome to our dedicated page for POOLBEG PHARMA PLC news (Ticker: POLBF), a resource for investors and traders seeking the latest updates and insights on POOLBEG PHARMA PLC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect POOLBEG PHARMA PLC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of POOLBEG PHARMA PLC's position in the market.
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) announced the granting of US patents for two of its drug candidates: POLB 001, an immunomodulator targeting severe influenza, and POLB 002, an RNA-based intranasal therapy for respiratory infections. The patents enhance the company’s intellectual property position, with plans for further protection through continuation applications. The CEO indicated that these patents are vital for commercializing their products as they approach a human trial for POLB 001, with data expected by year-end, aiming for monetization thereafter.
Poolbeg Pharma has signed a GMP manufacturing contract to ensure sufficient supply of its lead asset, POLB 001, for clinical trials starting in June 2022. The immunomodulator targets severe influenza and has potential applications for other diseases by reducing harmful hyperinflammation. The company plans to monetize POLB 001 post-trial results through partnerships. Manufacturing has been ongoing since late 2021, with a validated process ready for multiple disease indications. This strategic move positions Poolbeg favorably in the growing infectious disease market.
Poolbeg Pharma (AIM:POLB, OTCQB:POLBF) held its Annual General Meeting on April 4, 2022, where all resolutions received over 99.9% approval. The company focuses on developing innovative products in the infectious disease sector using a capital light clinical model, aiming for faster and cost-effective development compared to traditional biotech approaches. Poolbeg targets the rapidly expanding infectious disease market projected to exceed $250bn by 2025, drawing on insights from over 20 years of human challenge trials.
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) announced the signing of a Clinical Trial Agreement with the Centre for Human Drug Research in the Netherlands. This allows for a human challenge study of POLB 001, set to begin in June 2022, with results expected by year-end. The trial aims to evaluate POLB 001's effectiveness in moderating hyper-inflammatory immune responses linked to severe influenza. This innovative approach targets the body's immune response, not the virus itself, potentially making it resilient to viral changes. The company plans to monetize findings through partnerships with larger pharmaceutical firms.
Poolbeg Pharma has commenced trading on the OTCQB Venture Market in the U.S. under the ticker POLBF, expanding its investor base without additional capital raise or reporting obligations. This move is expected to increase liquidity on the AIM market by providing U.S. investors with easier access to trade shares priced in U.S. dollars. The company aims to develop innovative infectious disease therapies, including POLB 001 for severe influenza, leveraging a capital-light model. Poolbeg's strategy includes potential future dual listing on a national exchange like Nasdaq.